Cardiac Amyloidosis: Internist and Cardiologist Insight

Cardiac amyloidosis (amyloid cardiomyopathy) is a disease damage to the heart caused by extracellular amyloid deposition. In some cases, there may be local damage to the structures of the heart, for example, the atria; more often, heart damage is part of a systemic (generalized) pathology. Depending on the amyloid precursor protein, 36 types of amyloidosis are described, among which hereditary and acquired forms are distinguished. Cardiac amyloidosis is diagnosed 1) in the case of the amyloid infiltration in the myocardial bioptates or 2) in the case of non-cardiac amyloid deposition and the left ventricular wall thickening >12 mm without arterial hypertension and other reasons. The heart is most often affected in AL-, ATTR-, AA-, AANF-types of amyloidosis. Cardiac amyloidosis should be considered in patients with a heart failure with an unclear etiology, especially with preserved left ventricular ejection fraction, refractory to treatment, with proteinuria and CKD 4-5, in patients with idiopathic atrial fibrillation and conduction disturbances, in patients with left ventricular wall thickening of unclear etiology, low ECG voltage, unexplained arterial hypotension and pulmonary hypertension. Screening for cardiac amyloidosis should include non-invasive methods such as electrophoresis and immunofixation of blood and urine proteins, the free light lambda and kappa chains of immunoglobulins, 99Tc-DPD scintigraphy, genetic testing (if hereditary variants of amyloidosis are suspected), as well as a histological examination of biopsy samples stained with Congo red and polarizing microscopy.

1. Hassan, W., et al., Amyloid heart disease. New frontiers and insights in pathophysiology, diagnosis, and management. Tex Heart Inst J, 2005. 32(2): p. 178-84.

2. Falk, R.H., et al., AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy. J Am Coll Cardiol, 2016. 68(12): p. 1323-41.

3. Mishra, S., et al., Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish. Am J Physiol Heart Circ Physiol, 2013. 305(1): p. H95-103.

4. Benson, M.D., et al., Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid, 2018. 25(4): p. 215-219.

5. Lysenko (Kozlovskaya) L.V., Rameev V.V., Moiseev S.V. Clinical guidelines for diagnosis and treatment of systemic amyloidosis. Klinicheskaya farmakologiya i terapiya = Clin Pharmacol Therapy 2020;29(1):13-24. DOI 10.32756/0869-5490-2020-1-13-24 [in Russian]

6. Karafiatova, L. and T. Pika, Amyloid cardiomyopathy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2017. 161(2): p. 117-127.

7. Fontana, M., et al., Myocardial Amyloidosis: The Exemplar Interstitial Disease. JACC Cardiovasc Imaging, 2019. 12(11 Pt 2): p. 2345-2356.

8. Pinney, J.H., et al., Systemic amyloidosis in England: an epidemiological study. Br J Haematol, 2013. 161(4): p. 525-32.

9. Gilstrap, L.G., et al., Epidemiology of Cardiac AmyloidosisAssociated Heart Failure Hospitalizations Among Fee-for-Service Medicare Beneficiaries in the United States. Circ Heart Fail, 2019. 12(6): p. e005407.

10. Reznik E.V., Stepanova E.A. , Nguyen T.L. et al. Chronic heart failure in patients with systemic amyloidosis. Cardiovascular therapy and prevention. In press [in Russian].

11. Desport, E., et al., Al amyloidosis. Orphanet J Rare Dis, 2012. 7: p. 54.

12. Bird, J., et al., UK Myeloma Forum (U KMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation o f newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol, 2009. 147(1): p. 22-42.

13. Kastritis, E. and M.A. Dimopoulos, Recent advances in the management of AL Amyloidosis. Br J Haematol, 2016. 172(2) : p. 170-86.

14. Quarta, C.C., et al., The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med, 2015. 372(1): p. 21-9.

15. Maurer, M.S., et al., Expert Consensus Recommendations for the Suspicion and Diagnosis of Transthyretin Cardiac Amy loidosis. Circ Heart Fail, 2019. 12(9): p. e006075.

16. Gillmore, J.D., et al., Guidelines on the diagnosis and investigation of AL amyloidosis. Br J Haematol, 2015. 168(2 ): p. 207-18.

17. Donnelly, J.P. and M. Hanna, Cardiac amyloidosis: An update on diagnosis and treatment. Cleve Clin J Med, 2017. 84( 12 Suppl 3): p. 12-26.

18. Hou, X., M.I. Aguilar, and D.H. Small, Transthyretin and familial amyloidotic polyneuropathy. Recent progress in un derstanding the molecular mechanism of neurodegeneration. FEBS J, 2007. 274(7): p. 1637-50.

19. Sekijima, Y., J.W. Kelly, and S. Ikeda, Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses. Curr Pharm Des, 2008. 14(30): p. 3219-30.

20. Gonzalez-Lopez, E., et al., Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J, 2015. 36(38): p. 2585-94.

21. Seferovic, P.M., et al., Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and p atient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail, 2019.

22. Damy, T., et al., Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J, 2016. 37(23): p. 1826-34.

23. Galat, A., et al., Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg? Eur Heart J, 2016 . 37(47): p. 3525-3531.

24. Castano, A., et al., Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with sev ere aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J, 2017. 38(38): p. 2879-2887.

25. Lopez-Sainz, A., et al., Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or co nduction disorders. Amyloid, 2019. 26(3): p. 156-163.

26. Gudkova A.Y., Semernin E.N., Polyakova A.A. et al. The spectrum of mutations of the transthyretin gene in a cohort of patients with chronic heart failure. Translational Medicine. 2016;3(1):34-38. https://doi.org/10.18705/2311-4495-2016-3-1-34-38. [in Russian].

27. Johnson, S.M., et al., The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol, 2012. 421(2-3): p. 185-203.

28. Ando, Y., et al., Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis, 2013. 8: p. 31.

29. Rapezzi, C., et al., Disease profile and differential diagnosis of hereditary transthyretin-related amyloidosis with exclusively ca rdiac phenotype: an Italian perspective. Eur Heart J, 2013. 34(7): p. 520-8.

30. Sekijima, Y., et al., The current status of the Tran sthyretin Amyloidosis Outcomes Survey (THAOS) in Japan. Amyloid, 2019. 26(sup1): p. 61-62.

31. Damy, T., et al., Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyret in Amyloidosis Outcomes Survey (THAOS). Eur Heart J, 2019.

32. Plante-Bordeneuve, V., et al., The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodology. Curr Med Res Opin, 2013. 29(1): p. 77-84.

33. Coelho, T., M.S. Maurer, and O.B. Suhr, THAOS — The Transthyretin Amyloidosis Outcomes Survey: init ial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin, 2013. 29(1): p. 63-76.

34. Real de Asua , D., et al., Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol, 2014. 6: p. 369-77.

35. Leone, O., et al., Amyloid deposition as a cause of atrial remodelling in persistent valvular atrial fibrillation. Eur Heart J, 2004 . 25(14): p. 1237-41.

36. Rocken, C., et al., Atrial amyloidosis: an arrhythmogenic substrate for persistent atrial fibrillation. Ci rculation, 2002. 106(16): p. 2091-7.

37. Neben-Wittich, M.A., et al., Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primar y amyloidosis. Am J Med, 2005. 118(11): p. 1287.

38. Reznik E.V., Gendlin G.E., Storozhakov G.I. Echocardiography in the practice of a cardiologist. Moscow: Practice; 2013. 212p. [in Russian].

39. Fonta na, M., et al., Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev, 2015. 20(2): p. 133-44.

40. Kwong, R.Y., et al., Characterization of Cardiac Amyloidosis by Atrial Late Gadolinium Enhancement Using Contrast-Enhanced Cardiac Magnetic Resonance Imaging and Correlation With Left Atrial Conduit and Contractile Function. Am J Cardiol, 2015. 116(4): p. 622-9.

41. Banypersad, S.M., et al., T1 mapping and survival in systemic lightchain amylo idosis. Eur Heart J, 2015. 36(4): p. 244-51.

42. Strouse, C., et al., Approach to a patient with cardiac amyloidosis. J Geriatr Cardiol, 2019. 16(7): p. 567-574.

43. Park, G.Y., et al., Diagnostic and Treatment Approaches Involving Transthyretin in Amyloidogenic Dise ases. Int J Mol Sci, 2019. 20(12).

44. Caobelli, F., et al., Quantitative (99m)Tc-DPD SPECT/CT in patients with suspected ATTR c ardiac amyloidosis: Feasibility and correlation with visual scores. J Nucl Cardiol, 2019.

45. Yamamoto, H. and T. Yok ochi, Transthyretin cardiac amyloidosis: an update on diagnosis and treatment. ESC Heart Fail, 2019. 6(6): p. 1128-1139.

46. Gopal, D.M., F. L. Ruberg, and O.K. Siddiqi, Impact of Genetic Testing in Transthyretin (ATTR) Cardiac Amyloidosis. Curr Heart Fail Rep, 2019. 16(5): p. 180-188.

47. Fajardo, J., et al., Clinical pat hway to screen for cardiac amyloidosis in heart failure with preserved ejection fraction. Amyloid, 2019. 26(sup1): p. 166-167.

48. Manolis, A.S., et al., Cardiac amyloidosis: An underdiagnosed/underappreciated disease. Eur J Intern Med, 2019. 67: p. 1-13.

49. Gertz, M.A., et al., Advances in the treatment of her editary transthyretin amyloidosis: A review. Brain Behav, 2019. 9(9): p. e01371.

50. Maurer, M.S., et al., Tafamidis Treatment for Patients with Transthyretin Amylo id Cardiomyopathy. N Engl J Med, 2018. 379(11): p. 1007-1016.

51. Wechalekar, A.D., et al., Guidelines on the management of AL am yloidosis. Br J Haematol, 2015. 168(2): p. 186-206.

52. Dember, L.M., et al., Eprodisate for the treatment of renal disease in AA amyloido sis. N Engl J Med, 2007. 356(23): p. 2349-60.

53. Zhu, H., J. Yu, and M.S. Kindy, Inhibition of amyloidosis using lowmolecular-weight heparins. Mol Med, 2001. 7(8): p. 517-22.

54. van der Hilst, J.C., et al., Lovastatin inhibits formation of AA amyloid. J Leukoc Biol, 2008. 83(5): p. 1295-9.

55. Gillmore, J.D., et al., Sustained pharmacological depletion of serum amyloid P component in patien ts with systemic amyloidosis. Br J Haematol, 2010. 148(5): p. 760-7.

56. Kluve-Beckerman, B., et al., Antisense oligonucleotide sup pression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis. Amyloid, 2011. 18(3): p. 136-46.

57. Kennel, S.J., et al., Phagocyte depletion inhibits AA amyloid accumulation in AEF-induced huIL-6 transgenic mice. Amyloid, 2014. 21(1): p. 45-53.

58. Oerlemans, M., et al., Cardiac amyloidosis: the need for early diagnosis. Neth Heart J, 2019. 27(11): p. 525-536.

59. Sucker, C., et al., Amyloidosis and bleeding: pathophysiology, diagnosis, and therapy. Am J Kidney Dis, 2006. 47(6): p. 947-55.

60. Ishiguro, K., et al., Elevation of Plasmin-alpha2-plasmin Inhibitor Complex Predicts the Diagnos is of Systemic AL Amyloidosis in Patients with Monoclonal Protein. Intern Med, 2018. 57(6): p. 783-788.